Cytocom, Inc. CBLI
Day range unavailable
52-week range unavailable
- Market cap
- 107.66M
- Shares out
- 33.96M
- Earnings date
- Aug 16, 2021
Key statistics
- Enterprise value
- 79.97M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 151.91K
- Total debt
- 2.00M
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 3.62
- 200-day average
- 3.62
Next earnings
Aug 16, 2021
Expected Aug 16, 2021. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 16, 2021 | Jun 1, 2021 | 0.00 | — | — | — |
| Aug 14, 2020 | Jun 1, 2020 | 0.00 | — | — | — |
| May 15, 2020 | Mar 1, 2020 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 24, 2014 | Cantor Fitzgerald | down | Buy | Hold |
| Mar 21, 2013 | Cantor Fitzgerald | init | — | Buy |
| Mar 20, 2013 | Cantor Fitzgerald | init | — | Buy |
| Dec 6, 2012 | Oppenheimer | init | — | Outperform |
| Dec 4, 2012 | Burrill & Company | init | — | Market Outperform |
About Cytocom, Inc.
Cytocom, Inc., a clinical-stage biopharmaceutical company, develops novel small molecule immunotherapies targeting cancer, autoimmune, inflammatory, and infectious diseases. Its platform, Advanced Immunomodulating Multi-receptor System (AIMS), offers noroxymorphone analogs multi-receptor modulating therapies and proenkephalin analogs multi-receptor modulating therapies. The company also has various clinical-stage development programs, including CYTO-200 for Crohn's disease, fibromyalgia, multiple sclerosis, and covid-19; CYTO-400 for hepatocellular and pancreatic cancer; and CYTO-600 for acute radiation syndrome, advanced solid tumors, and vaccine adjuvant. Cytocom, Inc. has a collaboration agreement with the La Jolla Institute for Immunology for research and development of new immune-modulating agents targeting toll-like receptors for the treatment of cancer, infectious, autoimmune, and chronic inflammatory diseases. The company is based in Fort Collins, Colorado.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cytocom.com
News
Cytocom, Inc. (CBLI) CEO Michael Handley on Q2 2021 Results - Earnings Call Transcript 
Cytocom, Inc. Reports Second Quarter 2021 Financial Results 
Cytocom, Inc. Announces Participation at Liberty University's Empowering the Kingdom Through Business Conference 
Cytocom, Inc. to Report Second Quarter 2021 Financial Results 
Cytocom Inc. Provides Updates on Key Clinical Programs for Crohn's Disease, Hematology, Pancreatic Cancer and COVID-19 
Cytocom Inc. Provides Update on Completed Merger with Cleveland BioLabs 
Cytocom, Inc. Receives Commitments for $90 Million in Equity and Debt Financing 
Cleveland BioLabs, Inc. and Cytocom Inc. Announce Call to Discuss Stockholder Meeting Vote Results and Proposed Merger 
CBLI Stock Price Increases Over 15% Pre-Market: Why It Happened 
Cleveland BioLabs, Inc. and Cytocom Announce Registration Statement and Proxy Statement for Previously Announced Merger Declared Effective by SEC
Your note
Sign in to keep a note on CBLI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARONSTAM PETER | Chief Financial Officer | Stock Award(Grant) | Jul 26, 2021 | 141,370 |
| BROWN JULIA R | Director | Stock Award(Grant) | Jan 7, 2015 | 116,482 |
| BUCKHEIT ROBERT | Chief Technology Officer | Stock Award(Grant) | Jul 26, 2021 | 24,378 |
| DICORLETO PAUL E | Director | Stock Award(Grant) | Jun 18, 2013 | 41,968 |
| HOHN DAVID C | Director | Stock Award(Grant) | Mar 12, 2014 | 43,049 |
| MCAVOY COZETTE M | Officer | Stock Award(Grant) | Jul 26, 2021 | 60,947 |